![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Press Releases
DiscoverX Partners with B’SYS GmbH to Expand SAFETYscan In Vitro Pharmacological Profiling Services
DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development announced their partnership with B’SYS GmbH to expand DiscoverX’s...
Press Releases
Eyevensys receives French regulatory approval to advance EyeCET platform
Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of...
Clinical Trials
Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
Inovio Pharmaceuticals, Inc. announced preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its...
Clinical Trials
Cytori Receives FDA Approval for Burn Clinical Trial Related to BARDA Contract
Cytori Therapeutics, Inc. announced that the U.S. FDA has approved an IDE for a pilot clinical trial to evaluate Cytori Cell Therapy™ in patients...
Production & Manufacturing
Industry 4.0 from Bosch: a new level of efficiency Digital and virtual support facilitate work processes
At interpack 2017, Bosch Packaging Technology shows how industry 4.0 solutions provide higher efficiency in modern manufacturing. “All of our industry 4.0 applications focus...
Drug Research
IBM Patents Machine Learning Model for Pharmaceutical Drug Discovery
IBM announced that its scientists have been granted a patent on machine learning models to predict therapeutic indications and side effects from various drug...
Industry Reports
Imprimis Pharmaceuticals acquires license to patented formulation for dry eye disease
Imprimis Pharmaceuticals Inc , an ophthalmology-focused pharmaceutical company, announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read